The Federal Circuit Bar Association (FCBA) Patent Litigation Committee will be offering a remote program entitled "Skinny Labels, Enablement, Venue, and More: Recent Developments in Hatch-Waxman Litigation" on May 11, 2021 from 1:00 to 2:00 pm (ET).  Coy Stull of Carlton Fields, P.A. will moderate a panel consisting of April Weisbruch of McDermott Will & Emery LLP, John Bateman of Parker Poe Adams & Bernstein LLP, and Christopher Bruno of McDermott Will & Emery LLP.  The panel will cover recent developments in the Hatch-Waxman and BPCIA litigation and legislation, in particular, the Federal Circuit decisions in Amgen Inc. v. Sanofi, GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc., Valeant Pharmaceuticals North America, LLC. v. Mylan Pharmaceuticals, Inc., as well as the Orange Book Transparency Act and the Purple Book Continuity Act.

The webinar is complimentary for FCBA members and students, $50 for government/academic/retired attendees, and $175 for private practitioners.  Those interested in registering for the program, can do so here.